Synapse - Works

Results (2639)

PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma

Meeting Abstract

Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0

Meeting Abstract

Manni, M.; Chiattone, C. S.; Prince, M. H.; Pavlovsky, A.; Tomuleasa, C.; Miranda, E.; Kriachok, I.; Hawkes, E. A.; Fiad, L.; Hitz, F.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy

Meeting Abstract

Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies

Meeting Abstract

Serganova, I.; Bucktrout, R.; Isshiki, Y.; Sarapulov, A.; Santella, A.; Rodriguez, M.; Chakraborty, S.; Brunschvig, S.; Qualls, D.; Vardhana, S.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL

Meeting Abstract

Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the phase 2 redirect study

Meeting Abstract

Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhaylova, N.; Marin‐Niebla, A.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma

Meeting Abstract

Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants

Meeting Abstract

Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Pirtobrutinib in covalent BTK‐inhibitor pre‐treated mantle cell lymphoma: Updated results, subgroup analysis from bruin with >3 years follow‐up from start of enrollment

Meeting Abstract

Cheah, C. Y.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; Alencar, A. J.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save